Effects of BisGMA on glutathione metabolism and apoptosis in human gingival fibroblasts in vitro

Aim of this study was to investigate the effects of the resin monomer BisGMA on the glutathione concentration (monobromobimane assay) and apoptosis (Annexin V/PI-assay) of cultured primary human gingival fibroblasts. Cells were treated for up to 24h with 0.001-0.25 mM BisGMA to determine growth curves using the DNA stain H33342. Subsequent Annexin V/PI-assays revealed that fibroblasts exposed to concentrations of 0.005-0.01 mM (non-cytotoxic) and 0.05 mM (ED(10)-concentration) showed no increase of the share of apoptotic cells compared to non-treated controls (5-8%), while 0.1 mM BisGMA (approximately ED(50)-concentration) caused a significant increase of the percentage of apoptotic cells (50%). Simultaneously to the induction of apoptosis, 0.1 and 0.25 mM of BisGMA caused a significant depletion of the intracellular GSH content after 18 h of incubation. Our results indicate that BisGMA at concentrations >0.1 mM causes an extreme depletion of the intracellular GSH pool as well as apoptosis.     

Alexithymia and facial emotion recognition in patients with eating disorders

OBJECTIVE: Patients with anorexia or bulimia nervosa are reported to show high levels of alexithymia and to have difficulties recognizing facially displayed emotions. The current study tested whether it could be that facial emotion recognition is a basic skill that is independent from alexithymia. METHOD: We assessed emotion recognition skills and alexithymia in a group of 79 female inpatients with eating disorders and compared them with a group of 78 healthy female controls. Instruments used were the Toronto Alexithymia Scale, the Facially Expressed Emotion Labeling (FEEL) test, and the revised Symptom Check List (SCL-90-R). RESULTS: There were no significant differences between patients and controls in their emotion recognition scores, but patients with eating disorders displayed significantly more alexithymia and psychopathology. Emotion recognition in patients was not related to alexithymia, psychopathology, or clinical symptoms. CONCLUSION: We suggest that the reported alexithymia of patients with eating disorders is complex and independent from basic facial emotion recognition.     

How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Cystinuria continues to be one of the most challenging stone diseases. During the latest decades our knowledge of the molecular basis of cystinuria has expanded. Today 160 different mutations in the SLC3A1 gene and 116 in the SLC7A9 gene are listed. The full implications of type A, B or AB status are not yet fully understood but may have implications for prognosis, management and treatment. Despite better understanding of the molecular basis of cystinuria the principles of recurrence prevention have remained essentially the same through decades. No curative treatment of cystinuria exists, and patients will have a life long risk of stone formation, repeated surgery, impaired renal function and quality of life. Therapy to reduce stone formation is directed towards lowering urine cystine concentration and increasing cystine solubility. Different molecules that could play a role in promoting nucleation and have a modulating effect on cystine solubility may represent new targets for cystinuria research. Investigation of newer thiol-containing drugs with fewer adverse effects is also warranted. Determining cystine capacity may be an effective tool to monitor the individual patient’s response. Compliance in cystinuric patients concerning both dietary and pharmacological intervention is poor. Frequent clinical follow-up visits in dedicated centres seem to improve compliance. Cystinuric patients should be managed in dedicated centres offering the complete range of minimal invasive treatment modalities, enabling a personalized treatment approach in order to reduce risk and morbidity of multiple procedures.     

Analysis of Disk Volume before and after CT-guided Intradiscal and Periganglionic Ozone–Oxygen Injection for the Treatment of Lumbar Disk Herniation

PurposeTo quantify the change in volume in herniated lumbar disk after computed tomography (CT)–guided intradiscal and periganglionic ozone–oxygen injection and to assess the effects of patient age, sex, and initial disk volume on disk volume changes.Materials and MethodsA total of 283 patients with lumbar radiculopathy received a single intradiscal (3 mL) and periganglionic (7 mL) injection of an ozone–oxygen mixture (ratio, 3:97; ozone concentration, 30 μg/mL). Under CT guidance, intradiscal and periganglionic injection was performed through an extraspinal lateral approach with a 22-gauge spinal needle. All disk volume changes were evaluated on CT 6 months after the procedure in all patients.ResultsInitial mean disk volume was 17.37 cm³ ± 4.70 (standard deviation; range, 8.12–29.15 cm³). Disk volume reduction (mean, 7.70% ± 5.45; range, 0.29%–22.31%) was seen in 96.1% of treated disks (n = 272) at 6 months after treatment and was found to be statistically significant (P < .0001). In 3.9% of patients (n = 11), disk volume increased (mean, 0.59% ± 0.24; range, 0.11%–0.81%). Patient age correlated negatively with disk volume reduction (r = ?0.505; P < .0001) at 6 months after treatment, whereas initial disk volume correlated positively with volume reduction (r = 0.225; P = .00014) after therapy. No correlation was noted between patient sex and disk volume reduction after treatment (P = .09).ConclusionsIntradiscal administration of medical ozone is associated with a statistically significant volume reduction of the herniated lumbar disk. The volume-reduction effect of ozone correlates negatively with the patient's age and positively with initial disk volume.